Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 14
Submit an article Journal homepage
321
Views
63
CrossRef citations to date
0
Altmetric
Reviews

Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence

Véronique Rabenda University of Liège, Department of Public Health, Epidemiology and Health Economics, CHU, Bât. B23, 4000 Liège, Belgium +32 4 366 25 19; +32 4 366 28 12; [email protected]
, MSc,
Michaël Hiligsmann University of Liège, Department of Public Health, Epidemiology and Health Economics, CHU, Bât. B23, 4000 Liège, Belgium +32 4 366 25 19; +32 4 366 28 12; [email protected]
, MSc &
Jean-Yves Reginster University of Liège, Department of Public Health, Epidemiology and Health Economics, CHU, Bât. B23, 4000 Liège, Belgium +32 4 366 25 19; +32 4 366 28 12; [email protected]
, MD PhD
Pages 2303-2315 | Published online: 29 Jul 2009

Bibliography

  • Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(Suppl 2):S3-7
  • Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
  • Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35
  • Ross PD. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 1996;156:1399-411
  • Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026-32
  • Schwenkglenks M, Lippuner K, Hauselmann HJ, Szucs TD. A model of osteoporosis impact in Switzerland 2000-2020. Osteoporos Int 2005;16:659-71
  • Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
  • Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
  • Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
  • McClung MR, Geusens P, Miller PD, et al. Effects of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
  • Chesnut III CH, Skag A, Christiansen C, et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Bone Miner Res 2004;19:1241-9
  • Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052-7
  • Gardner MJ, Flik KR, Mooar P, Lane JM. Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 2002;84-A(8):1342-8
  • Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 2004;15:120-4
  • Freedman KB, Kaplan FS, Bilker WB, et al. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 2000;82-A(8):1063-70
  • Rabenda V, Vanoverloop J, Fabri V, et al. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 2008;90:2142-8
  • Ettinger M, Gallagher R, Amonkar M, et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 2004;50(Suppl 1):S513-4
  • Recker RR, Gallagher R, Maccosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61
  • Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
  • Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922-8
  • Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007;18:271-7
  • Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
  • van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006;22:1757-64
  • Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008;19:511-7
  • Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008;19:811-8
  • Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-8
  • Sebaldt RJ, Shane LG, Pham B, et al. Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. J Bone Miner Res 2004;19(Suppl 1):S445
  • Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response:the IMPACT study. Calcif Tissue Int 2003;72:408
  • Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone 2007;41:882-7
  • Bronder E, Klimpel A. Unused drugs returned to the pharmacy-new data. Int J Clin Pharmacol Ther 2001;39:480-3
  • Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990;150:841-5
  • Berg JS, Dischler J, Wagner DJ, et al. Medication compliance: a healthcare problem. Ann Pharmacother 1993;27(9 Suppl):S1-24
  • McCombs JS, Thibaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
  • Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8
  • Burrell A, Wong P, Ollendorf D, et al. Defining compliance, adherence and persistence: ISPOR Special Interest Working Group. Value Health 2005;8:A194-5
  • Tosteson ANA, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
  • Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26:245-56
  • Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21
  • Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003;5:859-62
  • Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003;14:808-13
  • Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-19
  • Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007;120:251-6
  • Brankin E, Walker M, Lynch N, et al. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006;22:1249-56
  • Bart R, Goette S, Hadji P, Hammerschmidt T. Persistence and compliance with daily and weekly-administered bisphosphonates for osteoporosis treatment in Germany. Osteoporos Int 2005;16(Suppl 3):S45
  • Boccuzzi SJ, Foltz SH, Omar MA, Kahler KH. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 2005;16(Suppl 3):S3
  • Silverman SL, Cramer JA, Sunyecz JA, et al. Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12 months results from two retrospective databases [abstract W366]. J Bone Miner Res 2007;22(Suppl 1):454
  • Cooper A, Drake J, Brankin E, et al. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905
  • Boccuzzi SJ, Foltz SH, Omar MA, et al. Adherence and persistence associated with pharmacology treatment of osteoporosis. Osteoporos Int 2005;16(Suppl 3):S24
  • Hamilton B, McKoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;1:259-62
  • Ettinger B, Pressman AR, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient's instructions and discontinuation. J Manag Care Pharm 1998;4:488-92
  • Aki S, Eskiyurt N, Akarirmak U, et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med J 2003;44:961-7
  • Gold DT, Martin BC, Frytak JR, et al. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 2007;23:585-94
  • Goettsch WG, Penning F, Erkens JE, et al. Persistent bisphosphonate usage reduces the risk of hospitalizations for osteoporotic fractures. J Bone Miner Res 2005;20(Suppl 1):S278
  • Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
  • Curtis JR, Westfall AO, Cheng H, et al. The benefit of adherence with bisphosphonates depends on age and fracture type: results form an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008;23:1435-41
  • Jaglal S, Thiruchelvam D, Hawker G. Impact of adherence to osteoporosis medications on fracture rates: a population-based study. Presented at the American Society for Bone and Mineral Research 29th Annual Meeting; September, 2007; Honolulu, Hawaii, USA. Abstract 1275
  • Gothe H, Hadji P, Hoeer A, et al. Good persistence and adherence with oral bisphosphonates reduce fracture rate in patients with osteoporotic fractures. Calcif Tissue Int 2007;80(Suppl 1):S129
  • Cotte FE, Mercier F, De Pouvourville G. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther 2008;30:2410-22
  • Hoër A, Seidlitz C, Gothe H, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Preference and Adherence 2009;3:25-30
  • Lekkerkerker F, Kanis JA, Alsayed N, et al. Group for the Respect of Ethics and Excellence in Science (GREES). Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007;18:1311-7
  • Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61
  • Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35:488-97
  • Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
  • Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-45
  • Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
  • Hadji P, Benhamou CL, Devas V, et al. Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: results of BALTO II. Osteoporos Int 2006;17(Suppl 1):S69
  • Lewiecki EM, Babbitt AM, Piziak VK, et al. Adherence to and gastrointestinal tolerability of monthly oral and quarterly intravenous ibandronate in women with previous intolerance in oral bisphosphonates: a 12-month, open-label prospective evaluation. Clin Ther 2008;30:605-21
  • McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41:122-8
  • Saag K, Lindsay R, Kriegman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007;40:1238-43
  • Hiligsmann M, Rabenda V, Gathon HJ, et al. Clinical and economic implications of non-adherence with osteoporosis medications. Osteoporos Int 2009;20:S1,5
  • Sheehy O, Kindundu C, Barbeau M, Lelorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int 2009: published online 20 January 2009; doi:10.1007/s00198-008-0829-2
  • Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15
  • Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23
  • Delmas PD, Vrijns B, Roux C, et al. Reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. J Bone Miner Res 2003;18(Suppl 2):S374
  • Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005;4:CD000011
  • Seely EW, Ravnikar A, McClung BL. Patient-provider decisions about long-term therapy. Am J Manag Care 1998;4(2 Suppl):S70-S77
  • Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991;48:1978-88
  • Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once weekly alendronate 70 mg versus once daily 10 mg: a multicentre randomized open label crossover study. Clin Ther 2002;24:1871-86
  • Simon JA, Beusterien K, Leidy NK, et al. Women with postmenopausal osteoporosis express a preference for once-monthly versus once-weekly bisphosphonate treatment. Female Patient 2005;30:31-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.